Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: Q-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of Q2042
up to 600 million CAR-positive viable T cells
Medicare payment limit per unit (Q4 2026): $626,315.834
No published MUE for Q2042. CMS keeps some MUE values confidential, so this does not mean there is no daily unit limit.
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$626,315.834per up to 600 million CAR-positive viable T cells
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 17.294%
CMS note: “Inflation-adjusted coinsurance”
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $626,315.834 | up to 600 million CAR-positive viable T cells | 17.294% | +2.4% | Inflation-adjusted coinsurance |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $611,693.171 | up to 600 million CAR-positive viable T cells | 17.295% | −0.4% | Inflation-adjusted coinsurance |
Medicare hospital outpatient (OPPS) · Q4 2026
K Paid separately (non-pass-through drug or biological)
$626,315.834 per unit · APC 9194 · copayment $1,736.000 per unit
CMS note: “Inflation-adjusted coinsurance;Copayments capped at inpatient deductible of $1,736.00.”
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 00078-0846-19 | KymriahNovartis Pharmaceuticals Corporation | 1 × 1 | 1 | 1 | $626,315.83 | ASP | Q1 2021 – Q4 2026 | ListedKymriah |
| 00078-0958-19 | KymriahNovartis Pharmaceuticals Corporation | 1 × 1 | 1 | 1 | $626,315.83 | ASP | Q1 2021 – Q4 2026 | ListedKymriah |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2019 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $614,180.808 | up to 600 million CAR-positive viable T cells | 17.165% | +8.4% | Inflation-adjusted coinsurance |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $566,531.304 | up to 600 million CAR-positive viable T cells | 18.547% | −4.3% | Inflation-adjusted coinsurance |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $591,726.201 | up to 600 million CAR-positive viable T cells | 17.633% | +2.3% | Inflation-adjusted coinsurance |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $578,324.579 | up to 600 million CAR-positive viable T cells | 17.866% | −0.1% | Inflation-adjusted coinsurance |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $578,771.123 | up to 600 million CAR-positive viable T cells | 17.74% | +2.3% | Inflation-adjusted coinsurance |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $565,623.836 | up to 600 million CAR-positive viable T cells | 18.087% | +6.9% | Inflation-adjusted coinsurance |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $529,192.855 | up to 600 million CAR-positive viable T cells | 19.272% | +1.1% | Inflation-adjusted coinsurance |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $523,452.561 | up to 600 million CAR-positive viable T cells | 19.164% | +1.0% | Inflation-adjusted coinsurance |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $518,240.680 | up to 600 million CAR-positive viable T cells | 19.31% | +1.4% | Inflation-adjusted coinsurance |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $511,072.497 | up to 600 million CAR-positive viable T cells | 19.455% | +5.5% | Inflation-adjusted coinsurance |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $484,623.489 | up to 600 million CAR-positive viable T cells | 20% | — | Added October 2023 |
|---|